Faes Farma, S.a. · BME:FAE
Faes Farma — FY2024 Earnings Presentation
20 slides from Faes Farma's earnings presentation, February 2025
Slide 1: Business Evolution 2024
Business Evolution 2024 February 2025
Slide 2: Index
Index 1// 2// 3// Overview Business Results 2024 evolution 2024 and outlook
Slide 3: Overview 2024
Overview 2024 oF FAES FARMA
Slide 4: Highlights
Overview 2024 Highlights BUSINESS • 2024 ends with a growth in revenue of almost 8%, mainly driven by the good performance of Pharma, PERFORMANCE both in Spain and in international markets. We reached the high range of the outlook in both sales and EBITDA. • Solid cash generation once finished the i
Slide 5: Key figures
Overview 2024 Key figures Total 510 M€ 128.9M€ NET 111.4 M€ EBITDA* Income +7.8% +5.5% PROFIT*** +21.2% Income BENEFICIO Adjusted 200.6 M€ EBIT** 107.1 M€ NET PROFIT 94.6 M€ top 3 NETO*** +8.5% +4.2% +2.9% molecules (without Derio tax deductions) Total 107.6 M€ 291 M€ international BAI +4.6% +10.5%
Slide 6: Business evolution 2024
2// Business evolution 2024 6
Slide 7: Pharma portfolio grows at a solid pace
Business Evolution 2024 Pharma portfolio grows at a solid pace Total income by portfolio line Animal Pharma top 3 Nutrition and molecules 2024 2023 % Health 39% 10% Pharma 457.8 420.4 9% Pharma top 3 molecules 200.6 184.8 9% Rest of Pharma 257.2 235.6 9% Animal Nutrition and Health 52.3 52.7 -1% Tot
Slide 8: Evolution top molecules
Business Evolution 2024 Evolution top 3 molecules High single-digit growth in Spain (+7%) despite price adjustments, thanks to new formats. BILASTINE 125.6 M€ Positive performance in direct international markets (+11%) +3% Good performance in Spain (+8%), yet sales growth is mainly driven by perform
Slide 9: Overall positive trend in Pharma geographies
Business Evolution 2024 Overall positive trend in Pharma geographies Total income by business areas 2024 2023 % Animal Nutrition and Health Pharma Pharma 457.8 420.4 9% Pharma 10% Spain Pharma Spain 174.5 161.8 8% 34% Licenses Pharma International (without licenses) 179.5 159.1 13% 21% Pharma Licens
Slide 10: Pharma Spain: The different channels are evolving positively
Business Evolution 2024 Pharma Spain: The different channels are evolving positively INCOME PHARMA SPAIN Highlights 2024 M€ 2024 2023 %var PRESCRIPTION Spain Pharma 174.5 161.8 8% Positive evolution in prescription sales during the year, especially in the respiratory franchise (+25%). Hidroferol gre
Slide 11: Pharma international (without licenses). Continued good performance in all areas
Business Evolution 2024 Pharma international (without licenses). Continued good performance in all areas 2024 2023 %var International (withour licenses) 179.5 159.1 13% Highlights 2024 Subsidiaries LATAM 95.5 85.6 12% FAES LATAM Central American Caribbean 28.8 26.6 • The positive evolution of Mexico
Slide 12: Licenses. Growth in line with expectations fuelled by licences for 'other products'
Business Evolution 2024 Licenses. Growth in line with expectations fuelled by licences for ‘other products’ Highlights 2024 INCOME LICENSES M€ BILASTINE 2024 2023 %var • Strong growth in markets such as Asia Pacific, Canada, Poland, Italy, Turkey, Israel and Chile, helping to offset the price reduct
Slide 13: Farm Faes. Stabilisation of the business while preparing the new stage of growth
Business Evolution 2024 Farm Faes. Stabilisation of the business while preparing the new stage of growth driven by the new industrial plant. Highlights 2024 INCOME FARM FAES M€ • Revenues are slightly down versus last year, 2024 2023 %var affected by the drop in raw materials which has reduced our a
Slide 14: Results and outlook
3// Results and outlook 14
Slide 15: Positive evolution of the main KPI's
Results and outlook 2024 Positive evolution of the main KPI´s Thousand € 2024 2023 %change Ordinary income (sales) 493.647 451.168 9,4% Highlights 2024 Other operating income 16.394 21.926 -25,2% Tota Income 510.041 473.094 7,8% • Growth in sales revenue reaching the upper end of the target range. C
Slide 16: Increased cash generation after reaching the final phase of industrial investments
Results and outlook 2024 Increased cash generation after reaching the final phase of industrial investments CASH FLOW Highlights 2024 Thousand € 2024 FINANCIAL SITUATION 107.576 Positive financial situation and cash generation once finished Profit before tax the phase of heavy industrial investments
Slide 17: 2024 landed on the high end of the guidance for both sales and EBITDA
Results and outlook 2024 2024 landed on the high end of the guidance for both sales and EBITDA Actual 2024 Guidance 2024 Growth Growth Total income +7.8% 6-8% Growth Growth EBITDA +5.5% 3-5% 17
Slide 18: Sustainability: positive performance and progress in 2024
Sustainability: positive performance and progress in 2024 DOUBLE MATERIALITY ANALYSIS We expand the identifications and …identifying opportunities in ESG assessment of ESG risks to... …understanding how we impact the environment and society E Environment S Social G Governance 40% 50% 50% 54% female
Slide 19: Faes Farma - Caring for tomorrow, today
cl FAES FARMA Caring for tomorrow, today
Slide 20: Disclaimer
DISCLAIMER This presentation has been prepared and published by Faes Farma Group and is presented for informational purposes only. This presentation is not a brochure, nor is it an offer or recommendation to make an investment. This presentation does not imply any subscription commitment, nor an off